Short answer: "High risk" is a payments label, not a product quality label. Acquiring banks put research peptides, medicines and telehealth, and large parts of fashion and jewellery in the same bucket for four reasons: regulatory ambiguity, intellectual property exposure, high-ticket or subscription chargeback patterns, and card-not-present fraud. Sourcing well in these categories in 2026 means picking suppliers who reduce those four risks rather than add to them, because the same supplier decisions that keep customers happy are the ones that keep your merchant account open. If you already know what you're selling and just need it processed, tell us about your business and we'll come back with options for your jurisdiction within one working day.
I run businesses in three of these four categories myself, and I place merchants in all of them with acquirers worldwide through UniqPay. What follows is what actually matters in each.
What "high risk" means to the people who move your money
Before the category-by-category detail, it's worth being precise about why a bank flags a product, because it tells you what to fix. Regulatory ambiguity: is the product legal to sell as presented in the customer's country, and is that easy to prove? IP exposure: could a rights holder force the scheme to shut you down? Chargeback profile: high tickets, subscriptions, long delivery windows and "not as described" disputes all raise the ratio, and Visa's VAMP threshold in 2026 sits at 1.5% with Mastercard's programmes biting earlier. Fraud: card-not-present sales of resellable goods attract stolen-card fraud.
Every sourcing decision below is really a decision about one of those four. Choose suppliers that shrink them and underwriting gets easy. Choose suppliers that grow them and no processor will save you.
Research peptides
Almost all peptide synthesis happens in China or India regardless of the vendor's address, so a supplier's real job is testing and chain of custody. The three models are wholesale (hold stock, best margins, you can re-test), white label (their product, your brand, faster to launch, you still own the compliance exposure), and dropshipping (zero inventory, but you never see the product and your name is on the disputes). Serious operators go wholesale or white label with a small starter order, independent testing, then a second supplier as backup.
Vet on the certificate of analysis: batch-specific, from a named independent lab, with the HPLC chromatogram (not just a purity number), mass spectrometry identity, and endotoxin results. GLP-1 analogues are the most commonly mislabelled compounds in 2025–26 testing because a truncated fragment can pass HPLC purity while having the wrong molecular weight. Prices far below market, in-house-only testing, pre-mixed solutions and identical 99.0% results on every batch are the red flags.
The payments link is direct: RUO acquirers decline sites and labels that make human-use claims, use pharmaceutical brand names or sell injection supplies alongside compounds. Your supplier's label wording has to match the positioning you'll be underwritten on. Stripe, Shopify Payments, PayPal and Square prohibit the category in every market, so plan the acquirer before the first stock order. There's more detail in our peptide sourcing guide and peptide payment processing guide.
Medicines, telehealth and GLP-1
This is the category where sourcing and licensing are inseparable. In 2026 the legal compounded GLP-1 market in the US has largely collapsed: after the FDA removed semaglutide and tirzepatide from the shortage list, mass compounding lost its basis, and by spring 2026 the FDA had proposed removing them from the 503B bulks list. Big telehealth names have exited compounded GLP-1s for branded product, and manufacturer direct-to-patient programmes now sell brand-name pens at fixed monthly prices. What still works is state-licensed 503A patient-specific compounding on a genuine prescription, branded product through licensed pharmacies, and equivalent registered-pharmacy models in Europe, the UK, Australia and elsewhere.
Sourcing therefore means choosing pharmacy partners, not product partners: accredited compounding or dispensing pharmacies that will name themselves publicly, provide COAs, and are licensed for every jurisdiction you ship into. Never source medicines from "research-only" suppliers or unlicensed importers; it's unlawful nearly everywhere and no acquiring bank will knowingly touch it.
Payments follow licensing. Card schemes require LegitScript certification for online prescription sales, which takes two to four weeks, and acquirers with healthcare underwriting programmes will want prescriber agreements, pharmacy licences and clear recurring-billing disclosures. Do it right and telehealth is one of the most placeable high-risk verticals of 2026, with tokenised card-on-file, retry logic and dispute alerts built in. Mix a research catalogue with a clinical one on the same site and you'll lose both accounts.
Apparel and fashion
Clothing isn't high risk by default; specific models are. Print-on-demand and dropshipped fast fashion carry long delivery windows and "not as described" chargebacks. Designer-inspired, "dupe" and unbranded-lookalike apparel sits in an IP grey zone that makes acquirers nervous. Anything explicitly replicating a brand's trademark is counterfeit: card schemes prohibit it, banks will terminate and MATCH-list you, and no reputable introducer will place it, us included.
If you're sourcing apparel that will be underwritten as high risk, buy from suppliers who let you own the design. Alibaba, Made-in-China and Global Sources suit wholesale runs with MOQs; DHgate and AliExpress suit small tests but seller quality varies enormously and dispute rates on those platforms are a leading indicator of the dispute rate your own customers will produce. Direct factory relationships and proxy agents on 1688 give the best pricing but need someone who reads Chinese and a solid inspection process. Whatever the source, insist on pre-shipment photos, samples in hand before you list, realistic delivery promises on your product pages, and no borrowed brand names or logos anywhere in the catalogue.
For payments, unbranded fashion with clean IP, tracked shipping and a fair returns policy will usually be underwritten domestically at near-standard ecommerce rates. Grey-zone catalogues get placed offshore at higher cost, if at all. Descriptors, delivery times and refund policies are what underwriters read first, because those are what generate the disputes.
Jewellery and watches
Jewellery gets flagged for high average tickets, resale value (fraudsters love it), and IP in the "designer-style" and homage segments. Lab-grown diamond and moissanite pieces, homage watches and unbranded fine jewellery are all placeable in 2026 provided the branding is your own; anything carrying a protected mark or a lookalike logo is not, for the reasons above.
Sourcing well here is about authenticity documentation and fraud tooling. For gemstones and precious metals, insist on grading reports and assay or hallmarking where the destination market requires it, and buy from suppliers who will put lot numbers on invoices. For homage watches, choose movements and case suppliers you can name on the product page, and describe the piece by its own specification rather than by the reference it resembles. High-value parcels need signature-on-delivery, insurance and photographic proof of packing, because "item not received" on a $1,500 order is a chargeback you will otherwise lose.
Payments: expect address verification, 3-D Secure and velocity rules as conditions of a domestic account, and a rolling reserve while you build history. Get those right and jewellery processes cleanly; skip them and the fraud rate does the underwriter's job for them.
The sourcing checklist that works across all four
- Test before you scale, in whatever form the category demands: independent lab results, a pharmacy licence check, physical samples, a grading report.
- Own the brand and the presentation, so no supplier can drag you into an IP or medical-claim problem.
- Document the chain — COAs, invoices with lot numbers, inspection photos, licences — because underwriters and dispute teams both ask for it.
- Keep a second supplier live so a single factory or pharmacy problem doesn't stop fulfilment.
- Match every product page, label and descriptor to what the acquirer approved.
The part that decides whether the business survives
Across all four categories the failure pattern is identical. Months of supplier work, real money into stock or licences, a clean site, an aggregator payment account, and then a permanent limitation with 90 to 180 days of funds frozen because the category was never underwritten. The fix isn't a smarter workaround; it's a dedicated high-risk merchant account with a bank that knowingly accepts your catalogue, plus a second rail (local account-to-account payments, ACH, open banking or card-to-crypto settlement) so one bank's review can't take you offline.
UniqPay is an introducer, not a single processor. We place peptide, telehealth, apparel and jewellery merchants across US, European and offshore acquirers depending on where you're incorporated, where your customers are and what's in the catalogue, and we tell you before you apply which supplier, label or product-page choices will get you declined. Typical domestic placements run 3.5–5.5% with a 5–10% rolling reserve and approvals in 3–7 working days for a prepared file; offshore is slower and dearer but exists for merchants in markets with no domestic option.
What happens when you get in touch
Fill in the form below and you'll hear from me directly. Tell me what you sell, where you're incorporated, where your customers are, roughly what volume, and whether you've been shut down anywhere before. Within one working day you'll get an honest read on which acquirers fit, what the rate and reserve will look like, and what to fix on the site or the sourcing side first. If you're still choosing suppliers, that's the best time to talk, because we can help you build the operation to pass underwriting rather than fail it. There's no fee to talk and no fee to apply; we're paid by the acquirer when you're live.
Get a high-risk merchant account quote →
FAQ
Which of these categories is hardest to get processing for in 2026?
Research peptides and compounded medicines, because of scheme-level restrictions and this year's Mastercard BRAM tightening. Licensed telehealth with LegitScript is comparatively easy. Unbranded apparel and jewellery are the easiest of the four when IP and fraud controls are clean.
Can I dropship in these categories?
You can, but dropshipping increases the very risks that get you flagged: you can't verify product, delivery windows stretch, and disputes land on you. Where the model is used, choose suppliers who provide inspection evidence and fast shipping, and expect underwriters to ask about it.